Company Legal Name
Latest Valuation
Founded Year
Headquarter
Tempus Labs, Inc. develops software platforms and genomic testing tools that enable personalized cancer treatment and clinical trial matching for patients and healthcare providers. Founded in 2015 and headquartered in Chicago, the company leverages artificial intelligence and machine learning to analyze clinical and molecular data, helping oncologists make more informed treatment decisions. Tempus has established partnerships with leading cancer centers and pharmaceutical companies, building one of the world's largest libraries of clinical and molecular data. The company continues to expand its precision medicine capabilities, focusing on advancing personalized healthcare through data-driven insights and improving patient outcomes across oncology.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





